icon bookmark-bicon bookmarkicon cameraicon checkicon chevron downicon chevron lefticon chevron righticon chevron upicon closeicon v-compressicon downloadicon editicon v-expandicon fbicon fileicon filtericon flag ruicon full chevron downicon full chevron lefticon full chevron righticon full chevron upicon gpicon insicon mailicon moveicon-musicicon mutedicon nomutedicon okicon v-pauseicon v-playicon searchicon shareicon sign inicon sign upicon stepbackicon stepforicon swipe downicon tagicon tagsicon tgicon trashicon twicon vkicon yticon wticon fm
6 Nov, 2025 22:03

Pharma rep collapses as Trump announces drug price cuts (VIDEO)

The US president has announced a new deal that would lower the price of some weight loss medications
Pharma rep collapses as Trump announces drug price cuts (VIDEO)

A pharmaceutical industry representative collapsed in the Oval Office on Thursday as members of US President Donald Trump’s administration were announcing a new deal for weight-loss medications.

The man was standing behind Trump during the event when his knees appeared to suddenly buckle underneath him. According to media outlets, he was initially identified as Novo Nordisk executive Gordon Finlay. However, the Danish company, which produces Ozempic, Rybelsus, and Wegovy, later denied that it was Finlay.

According to Fox News reporter Jacqui Heinrich, who witnessed the incident firsthand, Dr. Mehmet Oz, the administrator of the Centers for Medicare and Medicaid Services, assisted the executive as he collapsed, ensuring that he did not hit his head when he fell. Cabinet members attended to the man, propping up his legs, after reporters were escorted out of the Oval Office.

White House Press Secretary Karoline Leavitt later said “the gentleman is okay.”

Earlier in the Oval Office, Trump announced that prices of weight loss drugs like Ozempic would be “much lower.” The press conference featured executives from Novo Nordisk and another drug maker, Eli Lilly, which have worked with the administration on a deal to make weight loss medications, known as GLP-1s, more affordable.

Drugmakers will broaden access to popular obesity drugs like Ozempic, Wegovy, and Zepbound through TrumpRx, a new government website launching next year. Oral versions could start at $149 a month once cleared by the FDA. Injectable GLP-1 drugs will cost $245 a month for Medicare and Medicaid patients using them for approved conditions such as diabetes.

Dear readers! Thank you for your vibrant engagement with our content and for sharing your points of view. Please note that we have switched to a new commenting system. To leave comments, you will need to register. We are working on some adjustments so if you have questions or suggestions feel free to send them to feedback@rttv.ru. Please check our commenting policy
Podcasts
0:00
25:47
0:00
27:42